Cantor Fitzgerald Reiterates “Overweight” Rating for VolitionRx (NYSE:VNRX)

Cantor Fitzgerald reissued their overweight rating on shares of VolitionRx (NYSE:VNRXFree Report) in a report released on Thursday morning, Benzinga reports. Cantor Fitzgerald currently has a $2.50 target price on the stock.

Separately, started coverage on shares of VolitionRx in a research report on Sunday, May 12th. They set a sell rating on the stock.

Check Out Our Latest Research Report on VNRX

VolitionRx Stock Performance

Shares of VNRX stock opened at $0.77 on Thursday. VolitionRx has a 52-week low of $0.55 and a 52-week high of $1.79. The stock has a market cap of $63.77 million, a PE ratio of -1.67 and a beta of 1.26. The firm’s 50 day moving average price is $0.79 and its two-hundred day moving average price is $0.85.

VolitionRx (NYSE:VNRXGet Free Report) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The firm had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.27 million. As a group, sell-side analysts predict that VolitionRx will post -0.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On VolitionRx

A hedge fund recently bought a new stake in VolitionRx stock. Silverberg Bernstein Capital Management LLC acquired a new stake in VolitionRx Limited (NYSE:VNRXFree Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned approximately 0.19% of VolitionRx at the end of the most recent quarter. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

About VolitionRx

(Get Free Report)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.

Recommended Stories

Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with's FREE daily email newsletter.